Company StemCells Inc Nasdaq
Stocks
US85857R2040
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
Business description: StemCells Inc
Sales by Activity: StemCells Inc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Geographical breakdown of sales: StemCells Inc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: StemCells Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CEO | Chief Executive Officer | 54 | 1988-08-01 |
Rachel Vaknin
DFI | Director of Finance/CFO | 47 | 2022-03-31 |
Michal Ahuvia
COO | Chief Operating Officer | - | 2025-01-20 |
| Chief Tech/Sci/R&D Officer | 50 | 2023-11-30 | |
Simon Sharon
CTO | Chief Tech/Sci/R&D Officer | 65 | 2018-04-04 |
Composition of the Board of Directors: StemCells Inc
| Director | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CHM | Chairman | 54 | 2012-12-31 |
Scott Burell
BRD | Director/Board Member | 61 | 2016-11-27 |
Martin Madden
BRD | Director/Board Member | 65 | 2017-02-05 |
| Director/Board Member | 68 | 2017-12-11 | |
| Director/Board Member | 63 | 2020-03-31 | |
Tal Wenderow
BRD | Director/Board Member | 52 | 2020-07-31 |
| Director/Board Member | - | 2024-12-16 |
Company details: StemCells Inc
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.16% | -2.77% | -2.91% | +13.85% | 48.41B | |
| -0.40% | +2.16% | +418.57% | +554.47% | 45.01B | |
| -1.42% | +2.52% | +42.67% | +22.27% | 44.07B | |
| -1.22% | -0.37% | +4.82% | +84.42% | 40.73B | |
| -0.96% | -1.38% | +15.75% | +45.91% | 33.21B | |
| -0.21% | +2.86% | - | - | 17.77B | |
| -0.35% | -0.45% | +21.42% | +117.63% | 16.5B | |
| -1.54% | -1.30% | +12.16% | +31.14% | 14.45B | |
| -1.65% | +0.09% | +75.93% | +41.15% | 13.77B | |
| Average | -0.99% | +0.28% | +73.55% | +113.86% | 30.44B | |
| Weighted average by Cap. | -1.00% | -0.04% | +89.30% | +134.81% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- MBOT Stock
- Stock
- Company StemCells Inc
Select your edition
All financial news and data tailored to specific country editions
